| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
120,580,000 |
| Market
Cap: |
417.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.06 - $9.55 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. Co.'s platforms including Dolaflexin and Dolasynthen, deliver its auristatin DolaLock payload, as well as Immunosynthen, which delivers its stimulator of interferon genes (STING) agonist ImmunoLock payload. Co.'s product candidates include: upifitamab rilsodotin (UpRi), which is a Dolaflexin ADC targeting NaPi2b, an antigen expressed in ovarian cancer and other cancers; and XMT-1592, which is a Dolasynthen ADC targeting NaPi2b-expressing tumor cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
926,273 |
| Total Buy Value |
$0 |
$0 |
$0 |
$3,050,230 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
11 |
| Total Shares Sold |
0 |
65,329 |
69,149 |
116,233 |
| Total Sell Value |
$0 |
$177,041 |
$181,453 |
$451,673 |
| Total People Sold |
0 |
7 |
7 |
8 |
| Total Sell Transactions |
0 |
7 |
9 |
19 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  New Enterprise Associates 14, L.p. |
10% Owner |
– – • |
2020-04-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,000,000) |
7,959,520 |
|
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2020-04-09 |
4 |
A |
$0.00 |
$0 |
D/D |
497 |
497 |
|
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2020-04-09 |
4 |
A |
$0.00 |
$0 |
I/I |
61,146 |
1,146 |
|
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2020-04-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,060,000) |
0 |
|
- |
|
| Mott David M |
Director |
– • – |
2020-04-09 |
4 |
A |
$0.00 |
$0 |
I/I |
3,190 |
3,190 |
|
- |
|
| Hack Andrew A. F. |
Director |
– • – |
2020-04-07 |
4 |
B |
$5.59 |
$20,649,463 |
I/I |
3,445,667 |
3,445,667 |
2.1 |
152% |
|
| Mott David M |
Director |
– • – |
2020-04-07 |
4 |
B |
$5.59 |
$3,010,768 |
D/D |
538,599 |
538,599 |
2.39 |
152% |
|
| Sandell Scott D |
10% Owner |
– – • |
2019-08-28 |
4 |
S |
$2.91 |
$3,524 |
D/D |
(1,211) |
11,959,520 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2019-08-28 |
4 |
OE |
$0.05 |
$3,530 |
D/D |
70,593 |
11,960,731 |
|
- |
|
| Mott David M |
Director |
– • • |
2019-03-05 |
4 |
B |
$4.00 |
$15,000,000 |
I/I |
3,750,000 |
11,890,138 |
2.25 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2019-03-05 |
4 |
B |
$4.00 |
$15,000,000 |
D/D |
3,750,000 |
11,890,138 |
2.45 |
- |
|
| Lowinger Timothy B |
Chief Scientific Officer |
• – – |
2018-09-24 |
4 |
AS |
$11.63 |
$40,705 |
D/D |
(3,500) |
12,491 |
|
- |
|
| Lowinger Timothy B |
Chief Scientific Officer |
• – – |
2018-09-24 |
4 |
OE |
$1.40 |
$4,900 |
D/D |
3,500 |
15,991 |
|
- |
|
| Lowinger Timothy B |
Chief Scientific Officer |
• – – |
2018-08-27 |
4 |
AS |
$13.15 |
$46,025 |
D/D |
(3,500) |
12,491 |
|
- |
|
| Lowinger Timothy B |
Chief Scientific Officer |
• – – |
2018-08-27 |
4 |
OE |
$7.43 |
$26,005 |
D/D |
3,500 |
15,991 |
|
- |
|
| Lowinger Timothy B |
Chief Scientific Officer |
• – – |
2018-07-23 |
4 |
AS |
$11.06 |
$38,710 |
D/D |
(3,500) |
12,491 |
|
- |
|
| Lowinger Timothy B |
Chief Scientific Officer |
• – – |
2018-07-03 |
4 |
OE |
$1.40 |
$14,000 |
D/D |
10,000 |
15,991 |
|
- |
|
| Lowinger Timothy B |
Chief Scientific Officer |
• – – |
2018-02-21 |
4 |
OE |
$6.98 |
$41,259 |
D/D |
5,911 |
5,911 |
|
- |
|
| Foster Wayne |
Vice President of Finance |
• – – |
2018-01-30 |
4 |
OE |
$1.53 |
$44,582 |
D/D |
14,705 |
71,083 |
|
- |
|
| Protopapas Anna |
President and CEO |
• • – |
2017-12-20 |
4 |
OE |
$1.53 |
$15,938 |
D/D |
10,417 |
130,719 |
|
- |
|
| Barrett M James |
10% Owner |
– – • |
2017-07-03 |
4 |
B |
$15.00 |
$15,000,000 |
I/I |
1,000,000 |
8,140,138 |
1.5 |
- |
|
| Barrett M James |
10% Owner |
– – • |
2017-07-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,140,138 |
7,140,138 |
|
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2017-07-03 |
4 |
B |
$15.00 |
$15,000,000 |
I/I |
1,000,000 |
8,140,138 |
1.5 |
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2017-07-03 |
4 |
A |
$0.00 |
$0 |
I/I |
7,140,138 |
7,140,138 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2017-07-03 |
4 |
B |
$15.00 |
$15,000,000 |
I/I |
1,000,000 |
8,140,138 |
1.5 |
- |
|
245 Records found
|
|
Page 9 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.10 (2.98%) 
